Model-Informed Drug Development (MIDD) is an innovative approach revolutionizing the drug development process by using computational models and simulations to enhance decision-making and efficiency. By integrating key components like pharmacokinetic/pharmacodynamic (PK/PD) modeling, disease progression models, exposure-response relationships, and quantitative systems pharmacology (QSP), MIDD enables researchers to better predict drug behavior, optimize dosing, and reduce development costs. As the industry increasingly adopts this data-driven methodology, MIDD is becoming a vital tool in advancing more effective and personalized therapies.

The growing emphasis on patient-centricity in clinical research has led to widespread use of terms like "patient voice" and "patient engagement," but questions remain about whether these ideas drive real change or serve as PR buzzwords. As regulatory bodies push for more inclusive and practical study designs, the industry is recognizing the value of involving patients throughout the drug development process. When treated as strategic partners, patients can help refine study protocols, identify meaningful endpoints, and improve operational aspects—ultimately making trials more relevant and reducing barriers to participation.

Beyond the Data is a podcast that humanizes healthcare innovation by focusing on patient stories and the real-world impact of clinical research. Hosted by Drew, it features transparent, accessible conversations with experts and advocates on making trials more inclusive, reducing patient burdens, and driving patient-first approaches. The show bridges the gap between data and lived experience, offering a fresh perspective for anyone interested in the future of healthcare. Powered by SYNAPTIGEN, the podcast also highlights how strategic storytelling can elevate biotech and pharma brands.

Beyond the Data is a podcast that explores the emotional and human side of healthcare innovation, going beyond traditional clinical research conversations. Hosted by Drew, the show centers on patient stories, highlighting their resilience and the real-world impact behind every data point. Each episode addresses barriers in clinical trials, advocates for accessibility, and promotes inclusive, patient-first approaches. With expert guests ranging from scientists to healthcare advocates, the conversations are transparent, jargon-free, and accessible to all audiences. More than just a podcast, Beyond the Data is a movement reshaping how the industry connects with the people it serves. SYNAPTIGEN partners with leading content creators to craft powerful, strategic stories that simplify complex science and elevate brand engagement—contact us today to bring your message to life.

The Voice Behind Clinical Research and Patient Advocacy: Meet Beyond the Data Podcast Host Drew Harrison

Clinical research often feels impersonal, but Drew Harrison, CEO of SYNAPTIGEN Group, is committed to changing that by focusing on patient-first clinical trials. Through his podcast Beyond the Data, Drew shares the stories of patients and professionals alike, showcasing how data-driven decisions can also be patient-centered.

Xyzagen, Inc. is advancing neurological treatment with its groundbreaking Kv7 prodrug research, unveiled at the 2024 Society for Neuroscience Annual Meeting. With over 25 years of expertise in Kv7 ion channel science, Xyzagen introduced two patent-pending prodrugs—XYG203 and XYG204—designed to improve the efficacy and tolerability of ezogabine for conditions like neuropathic pain, epilepsy, and rare seizure disorders such as KCNQ2 DEE. Notably, XYG203 shows consistent absorption and reduced side effects, with strong efficacy demonstrated in rodent models of chronic pain. These innovations represent a major step forward in addressing unmet neurological needs.

In the evolving landscape of clinical research, the numbers tell only part of the story. Behind every data point is a person—a patient whose experience, perspective, and well-being shape the future of medicine. This is the driving force behind Beyond the Data, a podcast led by Drew Harrison, who is on a mission to shift the industry’s focus from statistics to the real human impact of research.